Skip to Main Content

Try STAT+ TODAY

courts

Most Read

Politics Rachel Cohrs

STAT Plus: Pharma’s likely to sue over Medicare negotiation. Here are the arguments they might use

Politics Nicholas Florko

STAT Plus: The FDA has just 3 days to decide how to regulate 6.5 million e-cigarette products. But what if it blows past the deadline?

Politics Nicholas Florko

STAT Plus: Federal judge blocks Trump rule to require drug prices in TV ads

First Opinion Kevin Doyle

Appeals court’s smart move paves the way for opioid addiction treatment in prisons and jails

First Opinion Bob Thomas

Genetic testing: the next big arena for fraud?

Business Rebecca Robbins and Damian Garde

Ex-Theranos CEO Elizabeth Holmes to return to court in July to set possible trial date

Politics Nicholas Florko

STAT Plus: An ICU staple has exponentially spiked in price. Can compounding solve that problem? Now the courts will decide

Politics Lev Facher

STAT Plus: Supreme Court deals a fatal blow to Maryland drug ‘price gouging’ law

All Coverage

First Opinion Nina Agrawal

As a pediatrician, I work with sexually assaulted teens. They deserve full investigations

Politics Lev Facher

STAT Plus: A drug distributor flagged a pharmacy’s suspicious opioid orders. A federal court says it has to keep shipping the pills

advertisement

First Opinion William W. Pinsky

Trump’s travel restrictions will make Americans sicker, not safer

Pharma Andrew Joseph

STAT Plus: Purdue, maker of OxyContin, launches major ad campaign to counter critics

First Opinion Debra Selkirk

A widow’s successful odyssey to change a discriminatory liver transplant policy

First Opinion David Mitchell

Allergan invokes the victim defense to protect a brand-name drug from a generic challenge

Pharmalot Ed Silverman

STAT Plus: In a sign of tougher FDA enforcement, Aegerion pays hefty fine for illegal marketing

Special Report Andrew Joseph

As a scientist, he studied trauma victims. Then he became one

The Pharmalot View Ed Silverman

STAT Plus: This pharma CEO won praise for his ‘social contract’ with the public. But his latest move could shred that pledge

Pharmalot Ed Silverman

STAT Plus: Allergan’s deal with the Mohawks raises troubling questions about the future of generics

Business Charles Piller

Proove Biosciences, which sold dubious DNA tests to predict addiction risk, sells off assets as CEO departs amid criminal probe

First Opinion Richard Gold

Eli Lilly’s Canadian odyssey to use a fake rule and fake news to protect bad patents

First Opinion Michael Burg

A Supreme Court pharma case deals consumers a big loss

Biotech Damian Garde

STAT Plus: The Shkreli saga: What’s changed? What hasn’t? And what’s next?

Pharma Meghana Keshavan

STAT Plus: Shkreli is convicted of fraud. Can pharma finally slam the door on him?

The Pharmalot View Ed Silverman

STAT Plus: Dear Scott Gottlieb: Add new warnings to Paxil labels. You may save a life

Health Andrew Joseph

Man who triggered dozens of opioid overdoses sentenced to 18 years in prison